DWP 431

Drug Profile

DWP 431

Alternative Names: Bongros-BMP; Bongros/BMP-2; DWP-431; Novosis; NOVOSIS-Dental; rhBMP-2

Latest Information Update: 07 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Proteins
  • Mechanism of Action Bone morphogenetic protein 2 stimulants; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Alveolar bone loss
  • Phase III Spinal disorders

Most Recent Events

  • 12 May 2015 Phase III development is ongoing for Spinal disorders in South Korea
  • 16 Apr 2013 Launched for Alveolar bone loss in South Korea (Intralesional)
  • 30 Jun 2012 Daewoong Pharmaceutical completes a Phase-III trial in Alveolar bone loss (after maxillary sinus floor augmentation) in South Korea (NCT01634308)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top